Anzeige
Mehr »
Login
Samstag, 29.03.2025 Börsentäglich über 12.000 News von 695 internationalen Medien
Ad-hoc-News: Wieder Verdopplung? Montag massiver Turnaround und komplette Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PSZH | ISIN: US67577C1053 | Ticker-Symbol: 2H51
Tradegate
28.03.25
21:29 Uhr
0,744 Euro
+0,029
+3,98 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
OCUGEN INC Chart 1 Jahr
5-Tage-Chart
OCUGEN INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,7200,74012:55
0,7060,72428.03.

Aktuelle News zur OCUGEN Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
18.03.OCU200 von Ocugen schreitet mit Sicherheitsgenehmigung in nächste Studienphase voran121
18.03.Ocugen: Data and Safety Monitoring Board Reviews Cohort 1 Safety Data and Approves Dosing Cohort 2 in the Clinical Trial of OCU200-a Novel Fusion Protein for Diabetic Macular Edema452OCU200 has a very favorable safety and tolerability profileNo serious adverse events related to the study drug have been reportedDosing of the second cohort has been approved MALVERN, Pa., March 18...
► Artikel lesen
06.03.Ocugen (NASDAQ:OCGN) Announces Quarterly Earnings Results, Hits Estimates56
OCUGEN Aktie jetzt für 0€ handeln
06.03.Beyond The Numbers: 5 Analysts Discuss Ocugen Stock40
05.03.Ocugen, Inc. - S-8, Securities to be offered to employees in employee benefit plans6
05.03.Ocugen, Inc. - 10-K, Annual Report11
05.03.Ocugen, Inc. Q4 Loss Increases In Line With Estimates27
05.03.Ocugen GAAP EPS of -$0.05 in-line, revenue of $0.76M beats by $0.46M12
05.03.Ocugen Provides Business Update with Fourth Quarter and Full Year 2024 Financial Results257Reached an alignment with FDA on Phase 2/3 pivotal confirmatory clinical trial for OCU410ST for Stargardt disease potentially expediting clinical development by two to three yearsCompleted dosing...
► Artikel lesen
04.03.Ocugen Q4 2024 Earnings Preview19
03.03.Ocugen erhält EU-Zustimmung für Gentherapie-Klassifizierungen45
03.03.Ocugen, Inc. - 8-K, Current Report14
27.02.Ocugen aligns with FDA on confirmatory study for OCU410ST19
27.02.Ocugen, Inc. Announces FDA Alignment on Phase 2/3 Pivotal Confirmatory Clinical Trial for Modifier Gene Therapy Candidate OCU410ST for Stargardt Disease229MALVERN, Pa., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that...
► Artikel lesen
14.02.Why Ocugen (OCGN) Is Advancing Today69
13.02.Expert Outlook: Ocugen Through The Eyes Of 4 Analysts46
12.02.Ocugen, Inc. Announces Dosing Completion in the Phase 2 ArMaDa Clinical Trial for OCU410-a Multifunctional Modifier Gene Therapy for the Treatment of Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration264Completed Phase 2 enrollment with randomization of 51 subjects into treatment and control armsPhase 1/2 study (N=60) demonstrated favorable safety and tolerability profile with no serious adverse...
► Artikel lesen
12.02.Ocugen, Inc. - 8-K, Current Report8
03.02.Ocugen gets positive EU opinion for ATMP classification for OCU40051
03.02.Ocugen Announces Positive Opinion of European Medicines Agency's Committee for Advanced Therapies for Advanced Therapy Medicinal Product Classification for Modifier Gene Therapy Candidate OCU400 for Retinitis Pigmentosa199MALVERN, Pa., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
► Artikel lesen
Seite:  Weiter >>
72 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,9